Abstract

During the pandemic emergency in 2020, favipiravir, a pyrazine analog, is proposed as a providential antiviral agent against the COVID-19 infection. Fabric phase sorptive extraction (FPSE) and gas chromatography-mass spectrometry (GC-MS) have been developed and used for the first time to identify favipiravir (FAV) in pharmaceutical, forensic, and biological samples (human plasma, blood, and urine). FAV is extracted using FPSE, its derivatization using N, O-bis (trimethylsilyl) trifluoroacetamide (BSTFA), and GC-MS analysis are all part of the procedure. Placket-Burman Design (PBD) and Central Composite Design (CCD) were utilized for the screening of FPSE’s significant factors and their optimization, respectively, in the design of experiment-based optimization. For FAV, solgel polyethylene glycol (PEG) provided the highest extraction efficiency of all tested membranes. By GC-MS, the proposed method was found to be linear between 0.01 and 10 g mL-1 under ideal conditions. By GC-MS, the LODs and LOQs were as low as 0.001-0.0026 g mL1 and 0.003-0.0086 g mL1. Intra-day and between day precisions were under 5 and 10%, individually, showing great strategy accuracy.